title: Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.
authors.affiliation: Service des Maladies Infectieuses et Tropicales, H pital Rothschild, Paris, France.
authors.forename: P M
authors.initials: PM
authors.lastname: Girard
authors.forename: V
authors.initials: V
authors.lastname: Schneider
authors.forename: A
authors.initials: A
authors.lastname: Dehée
authors.forename: P
authors.initials: P
authors.lastname: Mariot
authors.forename: C
authors.initials: C
authors.lastname: Jacomet
authors.forename: N
authors.initials: N
authors.lastname: Delphin
authors.forename: F
authors.initials: F
authors.lastname: Damond
authors.forename: G
authors.initials: G
authors.lastname: Carcelain
authors.forename: B
authors.initials: B
authors.lastname: Autran
authors.forename: A G
authors.initials: AG
authors.lastname: Saimot
authors.forename: J C
authors.initials: JC
authors.lastname: Nicolas
authors.forename: W
authors.initials: W
authors.lastname: Rozenbaum
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D054303:HIV Reverse Transcriptase; D016049:Didanosine